Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Safety
This study has been completed.
Sponsored by: Sanofi-Aventis
Information provided by: Sanofi-Aventis
ClinicalTrials.gov Identifier: NCT00785850
  Purpose

The purpose of this study is to prove the safety in normal conditions of use.


Condition Intervention Phase
Hygiene
Drug: Dermacyd PH_DETINBACK (Lactic Acid)
Phase III

Drug Information available for: Lactic acid Ammonium lactate
U.S. FDA Resources
Study Type: Interventional
Study Design: Supportive Care, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Safety Dermatological Evaluation: Vaginal Mucous Irritation - Product Tested: Dermacyd PH_DETINBACK (Lactic Acid)Sweet Flower

Further study details as provided by Sanofi-Aventis:

Primary Outcome Measures:
  • The absence of irritation and the good acceptability will be evaluated using one specific scale which describes the intensity of the reaction. [ Time Frame: Througouht the study ] [ Designated as safety issue: No ]

Enrollment: 31
Study Start Date: August 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Dermacyd PH_DETINBACK (Lactic Acid)
Drug: Dermacyd PH_DETINBACK (Lactic Acid)

  Eligibility

Ages Eligible for Study:   10 Years to 20 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • Integral skin test in the region;
  • Use of cosmetic product of the same category;
  • willingness in following the study procedures and to be present in the clinic at the days and scheduled time;

Exclusion criteria:

  • lactation or gestational risk or gestation;
  • use of Anti-inflammatory, immunosuppression or anti-histaminic drugs;
  • Atopic antecedent or allergic to cosmetic product;
  • Active cutaneous disease in the evaluation area;
  • Diseases which cause immunology decrease, such as diabetes and HIV;
  • Endocrinal pathologies;
  • Intense solar exposure 15 days before the evaluation;
  • Treatment until four months before the selection

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00785850

Locations
Brazil
Sanofi-Aventis Administrative Office
Sao Paulo, Brazil
Sponsors and Collaborators
Sanofi-Aventis
Investigators
Study Director: Jaderson Lima Sanofi-Aventis
  More Information

Related Info  This link exits the ClinicalTrials.gov site

Responsible Party: sanofi-aventis ( Medical Affairs Study Director )
Study ID Numbers: LACAC_L_04301
Study First Received: November 4, 2008
Last Updated: November 4, 2008
ClinicalTrials.gov Identifier: NCT00785850  
Health Authority: Brazil: National Health Surveillance Agency

ClinicalTrials.gov processed this record on January 16, 2009